Abstract 4169: CReMEC initiative: Characterization of patient-derived colorectal tumor models and correlation with patient profile
Authors: Julien Sylvia , Merino-Trigo Ana , Lacroix Ludovic , Pocard Marc , Goéré Diane , Mariani Pascale , Landron Sophie , Bigot Ludovic , Nemati Fariba , Weiswald Louis-Bastien , Lantuas Denis , Morgand Loïc , Prévost Grégoire , Gonin Patrick , Dangles-Marie Virginie , Bruno Alain , Pierre Alain , Thé Hugues De , Soliman Hany , Nunes Manoel , Calvet Loreley , Vrignaud Patricia , Duchamp Olivier , Berthet Cyril 
Published: February 2011

Well characterized models representing the heterogeneity of human colorectal cancers (CRC) are needed to develop effective therapeutic agents. Establishment of such tools will allow a better prediction of the clinical outcome, taking into account the diversity of each patient tumor phenotype and genotype. For this purpose and with the financial support of the French Ministry of Industry, we have associated efforts from hospitals, academic groups, biotech and pharmaceutical companies. From May 2007 to January 2009, 86 surgical specimens [59 primary (P) tumors, 19 metastasis (M), and 8 peritoneal carcinomatosis (C)] were collected from CRC patients (with informed consents and negative HBV, HCV, and HIVs serologies). Tumor samples were subcutaneously xenografted in nude mice. The take rate was 57% (P), 55% (C), and 82% (M) with a difference in the take rate between tumor stages (p= 0.0184). We further engrafted in nude mice, SCID mice and nude rats. No significant difference in the take rate and growth was observed between the 2 mouse strains. Most of the mouse-growing tumors (95%) were successfully engrafted in nude rats, however their growth was significantly slower showing a more pronounced stromal component when compared with mice. Characteristics of our models are in accordance with the CRC clinical heterogeneity. Sequence analysis of 54 models has been performed and mutations were observed for KRAS (46%), APC (44%), TP53 (59%), BRAF (11%), PI3KCA (11%), FBXW7 (6%), CTNNB1 (2%), EGFR (2%), and 5/21 present a MSI status. Besides molecular markers, we compared the gene copy number using CGH technology before and after engraftment. The results exhibit high similarity between early passages of xenografts and the original clinical tumor samples. The histological structure and molecular profile were preserved, indicating the relevance of these models. Nevertheless the quality control is required to follow potential molecular deviation after multiple in vivo passages. The established models are being evaluated for ex vivo and in vivo sensitivities to colon anticancer drugs (5-FU, oxaliplatin, irinotecan and cetuximab). In vivo studies performed in our panel show 14/19 models sensitive to 5-FU, 1/19 to oxaliplatin, 7/8 to irinotecan, and 6/19 to cetuximab. We will present the correlation between pharmacological studies, molecular profile and patient clinical history. Preclinical studies on patient-derived tumor models will bring benefits to evaluate novel targeted therapeutic strategies and potentially help the stratification strategy for cancer patients.

Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4169.